

2023 Annual General Meeting

Board of Director Candidates

Jan Møller Mikkelsen

Jan Møller Mikkelsen founded Ascendis Pharma and has served as President and Chief Executive Officer, as well as Board member, since December 2007. From 2002 to 2006, Mr. Mikkelsen was President and Chief Executive Officer of LifeCycle Pharma A/S. From 2000 to 2002, Mr. Mikkelsen was President of the Pharmaceutical Division of Maxygen, Inc. Prior to that, Mr. Mikkelsen co-founded ProFound Pharma A/S, (a biopharmaceutical company acquired by Maxygen, Inc.), where he served as Co-Chief Executive Officer from 1999 to 2000. From 1988 to 1999, Mr. Mikkelsen held various positions at Novo Nordisk A/S, a global healthcare company, including Vice President of Protein Discovery. In late 2021, Mr. Mikkelsen was named Chairman of the Board of Directors of Hummingbird Bioscience, a clinical-stage biotechnology company. He received a Cand. Scient. degree in Biochemistry from the University of Odense, Denmark, and pursued his post-doctoral research at Children's Hospital in Oakland, California, U.S.

Lisa Bright Morrison

Lisa Bright, B.Sc., has served as a member of the board of directors since April 2017. Previously, she served as President International for Intercept Pharmaceuticals, Inc., a biopharmaceutical company, from July 2016 to January 2021. Prior to her appointment as President International, Ms. Bright held various senior leadership positions from November 2014 to July 2016 at Intercept Pharmaceuticals including Senior Vice President, Head of EUCA and Chief Commercial and Corporate Affairs Officer and Head of EUCA. During her tenure at Intercept, Ms. Bright has overseen the development of the global launch of an orphan medicine in the US and Europe, including building the commercial organization in the US establishment of legal affiliates and teams across Europe and Canada. From 2008 to November 2014, Ms. Bright held various leadership positions at Gilead Sciences Ltd., a biopharmaceutical company, including Vice President, Head Government Affairs, Europe, Asia, Middle East and Australasia, Vice President and Head of HCV Launch Planning, Vice President and Head of Northern Europe and General Manager, UK and Ireland. Prior to Gilead Sciences, Ms. Bright served in various positions of increasing responsibility at GlaxoSmithKline plc from 1997 to 2006 including VP, Commercial Planning and Operations, Global and Vice President General Manager NZ and Vice President Head of Sales, UK and Ireland. Prior to that, Ms. Bright also worked at Sanofi from 1992 to 1996 and GlaxoSmithKline from 1989 to 1992. Ms. Bright received her B.Sc. in Pharmacology from University College London, United Kingdom.

Bill Fairey

Mr. Fairey has served as a member of the board of directors since 2022. He currently serves as Executive Chairman of Respira Therapeutics, Inc., a clinical-stage company developing inhaled therapeutics for cardiopulmonary diseases, a position he has held since January 2022. Since August 2021, Mr. Fairey has also served as a director of both Mirum Pharmaceuticals, a publicly traded biotechnology company developing therapies for rare liver diseases, and Lung Therapeutics, Inc., a clinical-stage biopharmaceutical company.

Prior to Respira, Mr. Fairey was Executive Vice President and Chief Commercial Officer of MyoKardia, Inc., a publicly traded clinical-stage biopharmaceutical company, from 2019-2020, when the company was acquired by Bristol-Myers Squibb. From 2018-2019, Mr. Fairey served as Executive Vice President and Chief Operating Officer of ChemoCentryx, Inc., a publicly traded biopharmaceutical company developing therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. From 2001-2017, Mr. Fairey served in various positions of increasing responsibility at Actelion Pharmaceuticals, including as President of Actelion's U.S. division, as well as Vice President, Asia Pacific Region, Managing Director and Vice President, Australia Asia Pacific Region, President of Actelion Canada, and Vice President, Sales and Managed Markets. Mr. Fairey began his pharmaceutical career as Business Director, Healthcare Management for the Parke-Davis Division of Warner-Lambert from 1988-2000.

Mr. Fairey received a B.S. in Biology from the University of Oregon and an M.B.A. from Saint Mary's College of California.

Siham Imani

Siham Imani has served as a member of the board of directors since 2022. She currently serves as Executive Vice President Corporate Strategy of Servier, a global pharmaceutical group headquartered in France, a position she has held since April 2019. Prior to her current role, Ms. Imani was Servier's Director of Corporate Strategy from 2017-2019.

Before joining Servier, Ms. Imani held various positions of increasing responsibility at Ipsen, a French pharmaceutical company specializing in oncology, neuroscience and rare diseases, including Vice President European Business Unit Pediatric Endocrinology, Vice President Commercial Transformation & Support, Vice President Corporate Strategic Planning and Executive Committee Secretary, and Corporate Strategic Planning Director, from 2011-2017. Ms. Imani also served as Projects Director of Pierre Fabre Medicament, a French pharmaceutical company, from 2010-2011, and as Marketing & Clinical Manager and European Marketing Manager of Biosense Webster, part of the Johnson & Johnson Family of Companies, from 2005-2010.

Ms. Imani received a Master in Economics and a Master in Chemistry from École Polytechnique in Palaiseau, France and an M.B.A. from Stanford University.